Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schostak

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Der Urologe. Ausg. A|February 9, 2019
[Focal therapy for prostate cancer]M Schostak
Der Urologe. Ausg. A|July 5, 2020
[Focal therapy for prostate cancer-3.5 year follow-up with 92% rebiopsy rate]A Fehr, M Schostak
Der Urologe. Ausg. A|January 16, 2015
[Treatment of localized prostate cancer with high-intensity focused ultrasound]D Baumunk, M Schostak
Frontiers of Radiation Therapy and Oncology|June 12, 2008
Hormone therapy for prostate cancer - immediate initiationM Schostak, K Miller, M Schrader
Der Urologe. Ausg. A|July 22, 2017
[Non-PSA-expressing, solid, and growing mass of the prostate]F Christoph, S Ebrahimsade, M Schostak
Frontiers of Radiation Therapy and Oncology|June 12, 2008
Radical prostatectomy in the 21st century - the gold standard for localized and locally advanced prostate cancerM Schostak, K Miller, M Schrader
Onkologie|July 18, 2002
Adjuvant and salvage radiotherapy after radical prostatectomyS Höcht, T Wiegel, M Schostak, et al.
Der Urologe. Ausg. A|September 25, 2008
[Adjuvant and neoadjuvant drug therapy for prostate cancer]K Miller, M Lein, M Schostak, et al.
Der Urologe. Ausg. A|October 27, 2017
[Study on the prediction of AR-V7 and CTC circulation in patients with metastatic, castration-resistant prostate cancer (mCRPC) : Correlation between common clinical outcome parameters (rPFS, OS), CTC changes, and AR-V7 status (androgen receptor splice variant 7) in patients with mCRPC on first-line therapy with abiraterone acetate (STAR-V7)-study AP 96/17 of the AUO]H Rexer, P Hammerer, M Schostak, et al.
Aktuelle Urologie|September 6, 2018
H Rexer, P Hammerer, M Schostak, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Der Urologe. Ausg. A|February 9, 2019
[Focal therapy for prostate cancer]M Schostak
Der Urologe. Ausg. A|July 5, 2020
[Focal therapy for prostate cancer-3.5 year follow-up with 92% rebiopsy rate]A Fehr, M Schostak
Der Urologe. Ausg. A|January 16, 2015
[Treatment of localized prostate cancer with high-intensity focused ultrasound]D Baumunk, M Schostak
Frontiers of Radiation Therapy and Oncology|June 12, 2008
Hormone therapy for prostate cancer - immediate initiationM Schostak, K Miller, M Schrader
Der Urologe. Ausg. A|July 22, 2017
[Non-PSA-expressing, solid, and growing mass of the prostate]F Christoph, S Ebrahimsade, M Schostak
Frontiers of Radiation Therapy and Oncology|June 12, 2008
Radical prostatectomy in the 21st century - the gold standard for localized and locally advanced prostate cancerM Schostak, K Miller, M Schrader
Onkologie|July 18, 2002
Adjuvant and salvage radiotherapy after radical prostatectomyS Höcht, T Wiegel, M Schostak, et al.
Der Urologe. Ausg. A|September 25, 2008
[Adjuvant and neoadjuvant drug therapy for prostate cancer]K Miller, M Lein, M Schostak, et al.
Der Urologe. Ausg. A|October 27, 2017
[Study on the prediction of AR-V7 and CTC circulation in patients with metastatic, castration-resistant prostate cancer (mCRPC) : Correlation between common clinical outcome parameters (rPFS, OS), CTC changes, and AR-V7 status (androgen receptor splice variant 7) in patients with mCRPC on first-line therapy with abiraterone acetate (STAR-V7)-study AP 96/17 of the AUO]H Rexer, P Hammerer, M Schostak, et al.
Aktuelle Urologie|September 6, 2018
H Rexer, P Hammerer, M Schostak, et al.
Pageof 9